A Randomized Comparison of a Sirolimus-eluting Stent With Biodegradable Polymer Versus an Everolimus-eluting Stent With a Durable Polymer for Percutaneous Coronary Revascularization

Trial Profile

A Randomized Comparison of a Sirolimus-eluting Stent With Biodegradable Polymer Versus an Everolimus-eluting Stent With a Durable Polymer for Percutaneous Coronary Revascularization

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms BIOSCIENCE
  • Most Recent Events

    • 16 Nov 2016 Results of prespecified analysis of the BIOSCIENCE trial published in the American Journal of Cardiology
    • 01 Sep 2014 Profile integrated for the study protocol published in the American Heart Journal.
    • 20 Jun 2013 Planned End Date changed from 1 Apr 2017 to 1 May 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top